Single tyrosine mutation in AAV8 vector capsid enhances gene lung delivery and does not alter lung morphofunction in mice

Cellular Physiology and Biochemistry

Volumn 34, Issue 3, 2014, Pages 681-690

  Martini, Sabrina V ^a   Da Silva, Adriana L ^a   Ferreira, Debora ^a   Gomes, Karina ^a   Ornellas, Felipe M ^a   Lopes Pacheco, Miquéias ^a   Zin, Emilia ^a   Petrs Silva, Hilda ^a   Rocco, Patricia R M ^a   Morales, Marcelo M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adeno associated virus; Gene therapy; Lung function; Tyrosine mutant

Indexed keywords

DNA; ENDOTHELIAL CELL GROWTH FACTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PARVOVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; TYROSINE; CYTOKINE; GREEN FLUORESCENT PROTEIN; PRIMER DNA; SIGNAL PEPTIDE;

ADENO ASSOCIATED VIRUS 8; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG INSTILLATION; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; LUNG INJURY; LUNG MECHANICS; LUNG PARENCHYMA; MALE; MONONUCLEAR CELL; MORPHOMETRICS; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; SITE DIRECTED MUTAGENESIS; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; WILD TYPE; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; LUNG; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MUS;

ANIMALS; BASE SEQUENCE; CAPSID; CYTOKINES; DEPENDOVIRUS; DNA PRIMERS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MALE; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TYROSINE;

EID: 84906626314     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363033     Document Type: Article

References (31)

1. Gonçalves MA: Adeno-associated virus: from defective virus to effective vector. Virol J 2005;2:43.
2. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE: Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007;18:726-732.
3. Devaney J, Curley GF, Hayes M, Masterson C, Ansari B, O'Brien T, O'Toole D, Laffey JG: Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Crit Care 2013;17:R82.
4. Wang SY, Yang M, Xu XP, Qiu GF, Ma J, Wang SJ, Huang XX, Xu HX: Intranasal delivery of T-bet modulates the profile of helper T cell immune responses in experimental asthma. J Investig Allergol Clin Immunol 2008;18:357-365.
5. Halbert CL, Madtes DK, Vaughan AE, Wang Z, Storb R, Tapscott SJ, Miller AD: Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010;18:1165-1172.
6. Mueller C, Flotte TR: Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008;15:858-863.
7. Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-327.
8. Srivastava A: Adeno-associated virus-mediated gene transfer. J Cell Biochem 2008;105:17-24.
9. Grimm D, Kay M: From virus evolution to vector revolution: use of naturally occurring serotypes of adenoassociated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003;3:281-304.
10. Samulski RJ, Chang L, Shenk T: Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-3828.
11. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB: Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003;14:1079-1088.
12. Gao G, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sic U S A 2002;99:11854-11859.
13. Masat E, Pavani G, Mingozzi F: Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med 2013;15:379-389.
14. Lassance RM, Caroline PP, Martini S V, Castiglione RC, Gutierrez TM, Abreu SC, Antunes MA, Xisto DG, Cebotaru L, Petrs-Silva H, Zin WA, Guggino WB, Linden R, Rocco PR, Morales MM: Does the use of recombinant AAV2 in pulmonary gene therapy damage lung function? Respir Physiol Neurobiol 2008;160:91-98.
15. Wang RL, Mclaughlin T, Cossette T, Tang Q, Foust K, Campbell-Thompson M, Cruz P, Loiler S, Mueller C, Flotte TR: Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of α-1-antitrypsin using invasive and noninvasive delivery. Mol Ther 2009;17:81-87.
16. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C: Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-712.
17. Peden CS, Burger C, Muzyczka N, Mandel RJ: Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant aav2 (rAAV2)-mediated, but not raav5-mediated, gene transfer in the brain. J Virol 2004;78:6344-6359.
18. Daya S, Berns KI: Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008;21:583-593.
19. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A: Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008;105:7827-7832.
20. Qi YF, Li QH, Shenoy V, Zingler M, Jun JY, Verma A, Katovich MJ, Raizada MK: Comparison of the transduction efficiency of tyrosine-mutant adeno-associated virus serotype vectors in kidney. Clin Exp Pharmacol Physiol 2013;40:53-55.
21. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, Hauswirth WW: High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463-471.
22. Liu Y, Joo K-I Wang P: Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 2013;20:308-317.
23. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
24. Martin EL, Sheikh TA, Leco KJ, Lewis JF, Veldhuizen RA: Contribution of alveolar macrophages to the response of the TIMP-3 null lung during a septic insult. Am J Physiol Lung Cell Mol Physiol 2007;293:L779-789.
25. Weibel ER: Morphometry: stereological theory and practical methods; in: Gil J (ed): Models of Lung Disease-Microscopy and Structural Methods. New York, Marcel Dekker, 1990, pp 199-247.
26. Liu Y, Joo K-I, Wang P: Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 2013;20:308-317.
27. Qiao C, Yuan Z, Li J, Tang R, Li J, Xiao X: Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum Gene Ther Methods 2012;23:29-37.
28. Pang J, Dai X, Boye SE, Barone I, Boye SL, Mao S, Everhart D, Dinculescu A, Liu L, Umino Y, Lei B, Chang B, Barlow R, Strettoi E, Hauswirth WW: Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 2011;19:234-242.
29. Madsen D, Cantwell ER, O'Brien T, Johnson PA, Mahon BP: Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol 2009;90:2622-2633.
30. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 201;1813:878-888.
31. da Silva AL, Martini SV, Abreu SC, Samary C dos S, Diaz BL, Fernezlian S, de Sá VK, Capelozzi VL, Boylan NJ, Goya RG, Suk JS, Rocco PR, Hanes J, Morales MM: DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J Control Release 2014;180:125-133.